CliffBio
biologic

Tecentriq Hybreza

atezolizumab and hyaluronidase-tqjs

Loss of exclusivitySeptember 2036projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameTecentriq Hybreza
Active ingredientatezolizumab and hyaluronidase-tqjs
Strength1,875MG/15ML; 30,000UNITS/15ML (125MG/2,000UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2024
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found